Re: Zenith Abstract at AACR 2017 Meeting April 1-5

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Abstract at AACR 2017 Meeting April 1-5

in response to

Re: Zenith Abstract at AACR 2017 Meeting April 1-5

BearDownAZ

posted on Mar 08, 2017 01:34AM

I'm curious also as there is at least one patient that has been on ZEN-3694 for over 7 months now. From the conversation at the AGM in Dec these patients were pretty sick going into this trial.